Dr. Wang-Gillam on PF-04136309 Plus FOLFIRINOX in Pancreatic Adenocarcinoma

January 17, 2015

Conference | Gastrointestinal Cancers Symposium (ASCO GI)

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the combination of the CCR2 antagonist PF-04136309 with FOLFIRINOX for the treatment of patients with borderline resectable and locally advanced pancreatic adenocarcinoma.

A phase Ib study investigating the combination found that the toxicity was very comparable with the FOLFIRINOX regimen alone. Efficacy findings were promising, notes Wang-Gilliam. The study found that 48% of patients taking the combination had a partial response and 48% had stable disease.

<<<